UK drugs firm GSK vows to stop paying doctors for promoting its products
Print Edition
drugs firm GlaxoSmithKline will stop paying doctors to promote its drugs and scrap prescription targets for marketing staff — a first for an industry battling scandals over its sales practices, and a challenge for its peers to follow suit.
Britain’s biggest drugmaker also said yesterday it would stop payments to health care professionals for attending medical conferences as it tries to persuade critics it is addressing conflicts of interest that could put commercial considerations ahead of the best outcome for patients.
The move may force other companies to act, since the industry has been under fire for aggressive marketing in recent years.
“Where GSK leads we must hope that other companies will follow,” said Fiona Godlee, editor of the British Medical Journal and an influential campaigner against undue industry influence in medical practice. “But there is a long way to go if we are to truly extricate medicine from commercial influence. Doctors and their societies have been too ready to compromise themselves.”
GSK’s move comes amid a major bribery investigation in China, where police have accused it of funneling up to 3 billion yuan (US$494 million) to travel agencies to facilitate bribes to boost its drug sales.
However, the company said the measures were not directly related to its Chinese problems and were rather part of a broad effort to improve transparency.
In the United States, the industry’s biggest market by far, many companies have run into conflicts over improper sales tactics and GSK reached a record US$3 billion settlement with the US government last year over charges that it provided misleading information on certain drugs.
A number of other firms have taken steps to clean up their marketing practices and companies are being forced to disclose payments to doctors under US law.
Similar laws requiring firms to make public the names of doctors they have paid will take effect in Europe from 2016.
“This will undoubtedly change behavior and trigger a rethink of how some forms of continuing medical education are organized and funded,” said Richard Bergstrom, director general of the European Federation of Pharmaceutical Industries and Associations.
Shares in GSK, hit in recent months by its woes in China and a resulting fall in sales, slid 1.4 percent against a 0.3 percent dip on London’s FTSE index.
AstraZeneca said in 2011 it was scrapping payments for doctors to attend international congresses but others, until now, have not followed suit and GSK’s actions go further. An AstraZeneca spokeswoman said yesterday it had tightened up practices in 2011 so that its actions could not be seen as an inducement for doctors to prescribe its products.
Tim Reed, head of Health Action International, an Amsterdam-based non-government organization critical of Big Pharma, said the GSK move would increase pressure on other companies.
“I think other companies will follow suit — but one of the biggest problems is that the industry persists in regulating itself,” he said.
GSK Chief Executive Andrew Witty said his company’s actions were designed to ensure patients’ interests always came first.
“We recognize that we have an important role to play in providing doctors with information about our medicines, but this must be done clearly, transparently and without any perception of conflict of interest,” he said.
The decision to stop payments to doctors for speaking about medicines during meetings with other prescribers marks a big shift for a global industry that has always relied heavily on the influence of experts in promoting products.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
